Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis

NCT01353638 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
25
Enrollment
OTHER
Sponsor class

Stopped Primary endpoint (HSP) could not be analyzed with the specified method in the planned interim analysis; a method of increased sensitivity had to be established.

Conditions

Interventions

Sponsor

Christoph Aufricht